PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

6-month data of the LEVANT 2 trial presented at TCT 2013

New study examines safety and efficacy of drug coated baloon angioplasty for treatment of femoropopliteal artery disease

2013-10-31
(Press-News.org) Contact information: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
6-month data of the LEVANT 2 trial presented at TCT 2013 New study examines safety and efficacy of drug coated baloon angioplasty for treatment of femoropopliteal artery disease SAN FRANCISCO, CA – October 30, 2013 – The first clinical trial in the United States to study the use of drug coated balloons (DCB) for femoropopliteal artery disease found the procedure is promising for safety and efficacy at six months. Six month data of the LEVANT 2 trial was presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

An estimated 8-10 million Americans suffer from peripheral arterial disease (PAD), a chronic, debilitating condition that often results in a reduced quality of life, disability due to limb loss/amputation, and/or death. The femoropoliteal arteries that run between the hip and knee are the most commonly diseased arteries in peripheral circulation.

There are a number of minimally invasive therapies used to treat femoropopliteal disease, including standard percutaneous transluminal angioplasty (PTA) stents (both drug-eluting and bare metal), and atherectomy devices. Unfortunately, restenosis rates in the femoropopliteal arteries remain high due to the length and complexity of disease. LEVANT 2 is the first trial in the United States to examine the use of a drug coated balloon in the treatment of femoropopliteal artery disease. While this treatment is available in other countries, it is not currently approved in the United States.

The primary safety endpoint was composite freedom from all-cause peri-operative death and freedom at one year in the index limb from amputation, re-intervention, and index-limb-related death. The primary efficacy endpoints were primary patency of the target lesion at one year and absence of restenosis.

LEVANT 2 randomized 476 patients presenting with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery and a patent outlflow artery to the foot. After a successful protocol-defined pre-dilation, subjects unlikely to require a stent based on strict angiographic criteria were randomized 2:1 to the treatment with either a drug coated balloon (DCB) or PTA alone with a standard balloon.

At six months by Kaplan-Meier time-to-event analysis, primary patency of the treated vessel was higher among patients treated with a DCB (92.3 percent vs. 82.7 percent). Patients treated with DCB experienced similar freedom from major adverse events compared to the PTA group (94.0 percent in the DCB group and 94.1 percent in the PTA group). Repeat revascularization rates at this interim time point were low and consistent among both groups.

"During angioplasty, DCBs are designed to deliver an anti-proliferative drug directly to the tissues of the treated vessel wall, thus inhibiting neointimal hyperplasia and restenosis without the need for a permanent foreign body implant," said co-primary investigator, Kenneth Rosenfield, MD. Dr. Rosenfield is Section Head, Vascular Medicine and Intervention and Chairman, STEMI & Acute MI Quality Improvement Committee at Massachusetts General Hospital.

"These findings are an important step toward making this novel treatment available to patients in the United States."

###

The LEVANT 2 trial was funded by C.R. Bard and Lutonix. Dr. Rosenfield reported being a consultant for Abbott Vascular; equity in Primacea; research or fellowship support from Abbott Vascular, Atrium, Lutonix-C.R. Bard, and IDEV; board member of VIVA Physicians.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.

END



ELSE PRESS RELEASES FROM THIS DATE:

Procedural results from the RIBS V trial presented at TCT 2013

2013-10-31
Procedural results from the RIBS V trial presented at TCT 2013 Good outcomes with both drug-eluting stents and drug-eluting balloons in treating patients with bare metal stent restenosis SAN FRANCISCO, CA – October 30, 2013 – A clinical trial comparing the use of drug-eluting ...

Brain connectivity can predict epilepsy surgery outcomes

2013-10-31
Brain connectivity can predict epilepsy surgery outcomes Discovery from Case Western Reserve, Cleveland Clinic researchers may spare patients from disappointing results A discovery from Case Western Reserve and Cleveland Clinic researchers could provide ...

Results of the SMART-CASE trial presented at TCT 2013

2013-10-31
Results of the SMART-CASE trial presented at TCT 2013 New study compares conservative and aggressive revascularization strategies for coronary stenting based upon angiography alone SAN FRANCISCO, CA – October 30, 2013 – A new study shows that a conservative approach to ...

Too much texting can disconnect couples

2013-10-31
Too much texting can disconnect couples Couples shouldn't let their thumbs do the talking when it comes to serious conversations, disagreements or apologies. Brigham Young University researchers Lori Schade and Jonathan Sandberg studied 276 young adults around ...

Watching R-rated movies lessens importance of faith for young people, Baylor University study finds

2013-10-31
Watching R-rated movies lessens importance of faith for young people, Baylor University study finds Viewing R-rated movies leads to decreased church attendance and lessens importance of faith among young people, according to a study by a Baylor University researcher ...

Results of the ADVISE II trial presented at TCT 2013

2013-10-31
Results of the ADVISE II trial presented at TCT 2013 Trial examines benefits of using a new test to determine the severity of coronary artery disease SAN FRANCISCO, CA – October 30, 2013 – A new study supports the use of instantaneous wave-free ratio (iFR), to simplify ...

Tagging aquatic animals can disrupt natural behavior

2013-10-31
Tagging aquatic animals can disrupt natural behavior American and Canadian researchers have for the first time quantified the energy cost to aquatic animals when they carry satellite tags, video cameras and other research instruments. Studying fibreglass ...

Stress eaters may compensate by eating less when times are good

2013-10-31
Stress eaters may compensate by eating less when times are good When faced with stress, some people seem to lose their appetite while others reach for the nearest sweet, salty, or fatty snack. Conventional wisdom tells us that stress ...

Results of the SORT-OUT VI trial presented at TCT 2013

2013-10-30
Results of the SORT-OUT VI trial presented at TCT 2013 New study compares 2 newer generation drug-eluting stents with biocompatible and biodegradable polymers SAN FRANCISCO, CA – October 29, 2013 – A new study found that both drug-eluting stents (DES) with biocompatible ...

Researchers identify way to increase gene therapy success

2013-10-30
Researchers identify way to increase gene therapy success Scientists in The Research Institute at Nationwide Children's Hospital have found a way to overcome one of the biggest obstacles to using viruses to deliver therapeutic ...

LAST 30 PRESS RELEASES:

Attitudes, not income, drive energy savings at home

The playbook for perfect polaritons

‘Disease in a dish’ study of progressive MS finds critical role for unusual type of brain cell

Solar-powered method lights the way to a ‘de-fossilized’ chemical industry

Screen time linked to lower academic achievement among Ontario elementary students

One-year outcomes after traumatic brain injury and early extracranial surgery in the TRACK-TBI Study

Enduring outcomes of COVID-19 work absences on the US labor market

Affirmative action repeal and racial and ethnic diversity in us medical school admissions

Cancer progression illuminated by new multi-omics tool

Screen time and standardized academic achievement tests in elementary school

GLP-1RA order fills and out-of-pocket costs by race, ethnicity, and indication

Study finds HEPA purifiers alone may not be enough to reduce viral exposure in schools

UVA Health developing way to ID people at risk of dangerous lung scarring even before symptoms appear

How can we know when curing cancer causes myocarditis?

Male infertility in Indian men linked to lifestyle choices and hormonal imbalances

An acoustofluidic device for sample preparation and detection of small extracellular vesicles

The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances thera

A prototype LED as thin as wallpaper — that glows like the sun

Transnational electoral participation of undocumented Mexican immigrants in the US

A new method to build more energy-efficient memory devices for a sustainable data future

Freely levitating rotor spins out ultraprecise sensors for classical and quantum physics

‘Chinese lantern’ structure shifts into more than a dozen shapes for various applications

Towards light-controlled electronic components

Tiny architects, titanic climate impact: scientists call for October 10 to become International Coccolithophore Day

Stress sensitivity makes suicidal thoughts more extreme and persistent among the university population

Lessons from Ascension’s shark troubles could help boost conservation

Fire provides long-lasting benefits to bird populations in Sierra Nevada National Parks

Menstrual cycle affects women’s reaction time but not as much as being active

Housing associations more effective than government in supporting unemployed in deprived areas

Biochar helps composting go greener by cutting greenhouse gas emissions

[Press-News.org] 6-month data of the LEVANT 2 trial presented at TCT 2013
New study examines safety and efficacy of drug coated baloon angioplasty for treatment of femoropopliteal artery disease